A prospective observational study of the clinical efficacy and safety of intra-articular sodium hyaluronate in synovial joints with osteoarthritis

European Journal of Physical and Rehabilitation Medicine

Volumn 47, Issue 3, 2011, Pages 407-415

  Foti, C ^a   Cisari, C ^b   Carda, S ^b   Giordan, N ^c   Rocco, A ^a   Frizziero, A ^d   Della Bella, G ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^c Fidia Farmaceutici   (Italy)

^d UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Clinical trial; Hyaluronic acid; Injections; Intra articular; Osteoarthritis; Phase IV; Viscosupplementation

Indexed keywords

HYALURONIC ACID; LOCAL ANESTHETIC AGENT; VISCOSUPPLEMENT;

AGED; ARTICLE; CLINICAL TRIAL; FEMALE; HUMAN; INTRAARTICULAR DRUG ADMINISTRATION; MALE; MIDDLE AGED; OBSERVATION; OSTEOARTHRITIS; PAIN ASSESSMENT; PHASE 4 CLINICAL TRIAL; PROSPECTIVE STUDY; QUALITY OF LIFE; QUESTIONNAIRE; SYNOVIUM; TREATMENT OUTCOME;

AGED; ANESTHETICS, LOCAL; FEMALE; HUMANS; HYALURONIC ACID; INJECTIONS, INTRA-ARTICULAR; MALE; MIDDLE AGED; OBSERVATION; OSTEOARTHRITIS; PAIN MEASUREMENT; PROSPECTIVE STUDIES; QUALITY OF LIFE; QUESTIONNAIRES; SYNOVIAL MEMBRANE; TREATMENT OUTCOME; VISCOSUPPLEMENTS;

EID: 82355176399     PISSN: 19739087     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Arrich J, Piribauer F, Mad P, Schmid D, Klaushofer K, Mullner M. Intra-articular hyaluronic acid for the treatment of the knee: systematic review and meta-analysis. CMAJ 2005;172:1039-43. (Pubitemid 40546601)
2. Abatangelo G, O'Regan M. Hyaluronan: Biological role and function in articular joints. Eur J Rheumatol Inflamm 1995;15:9-15.
3. Ghosh P, Guidolin D. Potential mechanism of action of intraarticular hyaluronan therapy in osteoarthritis: Are the effects molecular weight dependent. Semin Arthritis Rheum 2002;32:10-37. (Pubitemid 35001162)
4. Carr AJ. Beyond disability: measuring the social and personal consequences of osteoarthritis. Osteoarthritis Cartilage 1999;7:230-8. (Pubitemid 29219670)
5. Karlsson J, Sjögren LS, Lohmander LS. Comparison of two hyaluronan drugs and placebo in patients with knee osteoarthritis. A controlled, randomized, double-blind, parallel-design multicentre study. Rheumatology 2002;41:1240-8. (Pubitemid 35363798)
6. Dougados M, Nguyen M, Listrat V, Amor B. High molecular weight sodium hyaluronate (hyalectin) in osteoarthritis of the knee: a 1 year placebo-controlled trial. Osteoarthritis Cartilage 1993;1:97-103.
7. Scale D, Wobig M, Wolpert W. Viscosupplementation of osteoarthritic knees with hylan: a treatment schedule study. Curr Ther Res 1994;55:220-32. (Pubitemid 24134800)
8. Adams ME, Atkinson MH, Lussier AJ, Schulz JI, Siminovitch KA, Wade JP et al. The role of viscosupplementation with Hylan G-F 20 (Synvisc) in the treatment of osteoarthritis of the knee: a Canadian multicenter trial comparing hylan G-F 20 alone, hylan G-F 20 with nonsteroidal anti-inflammatory drugs (NSAIDs) and NSAIDs alone. Osteoarthritis Cartilage 1995;3:213-25. (Pubitemid 26046657)
9. Lussier A, Cividino AA, McFarlane CA, Olszynski WP, Potashner WJ, De Medicis R. Viscosupplementation with hylan for the treatment of osteoarthritis: findings from clinical practice in Canada. J Rheumatol 1996;23:1579-85. (Pubitemid 26290585)
10. ®) in osteoarthritis of the knee. Osteoarthritis Cartilage 1997;5:153-60. (Pubitemid 27261990)
11. ® Study Group. J Rheumatol 1998;25:2203-12. (Pubitemid 28505869)
12. Wobig M, Dickhut A, Maier R, Vetter G. Viscosupplementation with hylan G-F 20: a 26-week controlled trial of efficacy and safety in the osteoarthritic knee. Clin Ther 1998;20:410-23. (Pubitemid 28343495)
13. Petrella RJ, DiSilvestro MD, Hildebrand C. Effects of hyaluronate sodium on pain and physical functioning in osteoarthritis of the knee. A randomized, double-blind, placebo-controlled clinical trial. Arch Intern Med 2002;162:292-8. (Pubitemid 34127406)
14. Raynauld JP, Torrance G, Band P, Goldsmith CH, Tugwell P, Walker V et al. Prospective, randomized, pragmatic, health outcomes trial evaluating the incorporation of hylan G-F into the treatment paradigm for patients with knee osteoarthritis (Part 1 of 2): clinical results. Osteoarthritis Cartilage 2002;10:506-17. (Pubitemid 34919065)
15. ®) in osteoarthritis. Rheumatology 2001;40:158-69.
16. ®) and methylprednisolone acetate on primary osteoarthritis of the knee. Osteoarthritis Cartilage 2001;9:371-81. (Pubitemid 32454781)
17. Frizziero L, Govoni E, Bacchini P. Intra-articular hyaluronic acid in the treatment of osteoarthritis of the knee: clinical and morphological. Clinical Exp Rheum 1998;16:441-9. (Pubitemid 28370856)
18. Huskisson EC, Donnelly S. Hyaluronic acid in the treatment of osteoarthritis of the knee. Rheumatol 1999;38:602-7. (Pubitemid 29507326)
19. Adams ME, Lussier AJ, Peyron JG. A risk-benefit assessment of injections of hyaluronan and its derivatives in the treatment of osteoarthritis of the knee. Drug Saf 2000;23:115-30. (Pubitemid 30601400)
20. Jüni P, Reichenbach S, Trelle S, Tschannen B, Wandel S, Jordi B et al. Efficacy and safety of intraarticular hylan or hyaluronic acid for osteoarthritis of the knee. Arthritis Rheum 2007;56:3610-9. (Pubitemid 350100694)
21. Owen DS. Diagnostic tests and procedures. Aspiration and Injection of Joints and Soft Tissue. In: Ruddy S, Harris ED, Sledge CB, editors. Kelly's textbook of rheumatology. Sixth edition. Philadelphia: WB Saunders; 2001. p. 583-5.
22. Allen E, Krohn K. Adverse reactions to hylan G-F 20. J Rheumatol 2000;27:6.
23. Bernardeau C, Bucki B, Liote F. Acute arthritis after intra-articular hyaluronate injection: Onset of effusions without crystal. Ann Rheum Dis 2001;60:518-20. (Pubitemid 32417427)
24. Martens PB. Bilateral symmetric inflammatory reaction to hylan G-F.20 injection. Arthritis Rheum 2001;44:978-9. (Pubitemid 32319792)
25. Chen AL, Desai P, Adler E, Di Cesare PE. Granulomatous inflammation after hylan G-F 20 viscosupplementation of the knee: a report of six cases. J Bone Joint Surg 2002;84 A: 1142-7.
26. Pullman-Mooar S, Mooar P, Sieck M, Clayburne G, Schumacher HR. Are there distinctive inflammatory flares of synovitis after hylan GF intra-articular injections? Arthritis Rheum 1999;42(Suppl 9): S295.
27. Puttick M P E, Wade JR, Chalmers A, Connell DG, Rangno KK. Acute local reactions after intraarticular hylan for osteoarthritis of the knee. J Rheumatol 1995;22:1311-4.
28. Rees JD, Wojtulewski JA. Systemic reaction to viscosupplementation for knee osteoarthritis. Rheumatology 2001;40:1425-6. (Pubitemid 34065379)
29. Guidelines on Post Market Clinical Follow Up, Medical Devices Guidance Document. 2004, MEDDEV2.12-2.
30. Fries JF, Spitz P, Kraines G, Holman H. Measurement of patient outcome in arthritis. Arthritis Rheum 1980;23:137-45. (Pubitemid 10164318)
31. Bruce B, Fries J. The Stanford health assessment questionnaire (HAQ): a review of its history, issues, progress, and documentation. J Rheumatol 2003;30:167-78. (Pubitemid 36077790)
32. Ranza R, Marchesoni A, Calori G, Bianchi G, Braga M, Canazza S et al. The Italian version of the Functional Disability Index of the Health Assessment Questionnaire. A reliable instrument for multicenter studies on rheumatoid arthritis. Clin Exp Rheumatol 1993;11:123-8. (Pubitemid 23155979)
33. EuroQol Group. EuroQol - a new facility for the measurement of health-related quality of life. Health Policy 1990;16:199-208.
34. Hurst NP, Jobanputra P, Hunter M, Lambert M, Lochhead A, Brown H. Validity of EuroQol - a generic health status instrument - in patients with rheumatoid arthritis. Economic and Health Outcomes Research Group. Br J Rheumatol 1994;33:655-62. (Pubitemid 24222119)
35. Schieb F. Intraartikular injizierte Hyaluronsaure bei Arthropathien. Arthritis Rheum 2003;6:338-40.
36. Hamburger MI, Lakhanpal S, Mooar PA, Oster D. Intra-articular hyaluronans: a review of product-specific safety profiles. Semin Arthritis Rheum 2003;32:296-309. (Pubitemid 36459279)
37. Goldberg VM, Coutts RD. Pseudoseptic reactions to hylan viscosupplementation: diagnosis and treatment. Clin Orthop 2004;419:130-7. (Pubitemid 38269682)
38. Smith MM, Ghosh P. The synthesis of hyaluronic acid by human synovial fibroblasts is influenced by the nature of the hyaluronate in the extracellular environment. Rheumatol Int 1987;7:113-22.
39. Yasui T, Akatsuka M, Tobetto K. Effects of hyaluronan on the production of stromelysin and tissue inhibitor of metalloproteinase-1 (TIMP-1) in bovine articular chondrocytes. Biomed Res 1992;13:343-8.
40. Creamer P, Sharif M, George E, Meadows K, Cushnaghan J, Shinmei M et al. Intra-articular hyaluronic acid in osteoarthritis of the knee: an investigation into mechanisms of action. Osteoarthritis Cartilage 1994;2:133-40. (Pubitemid 24208469)
41. Takahashi K, Goomer RS, Harwood F, Kubo T, Hirasawa Y, Amiel D. The effects of hyaluronan on matrix metalloproteinase-3 (MMP-3), interleukin-1 beta (IL-lbeta), and tissue inhibitor of metalloproteinase-1 (TIMP-1) gene expression during the development of osteoarthritis. Osteoarthritis Cartilage 1999;7:182-90. (Pubitemid 29219664)
42. Marshall KW. Intra-articular hyaluronan therapy. Curr Opin Rheumatol 2000;12:468-74.
43. Kelly M, Lieberman JR. Osteoarthritis of the knee: Focus on advances in treatment. Am J Orthop (Suppl) 2004;33:3-4.
44. DeVane CL. Substance P: a new era, a new role. Pharmacotherapy 2001;21:1061-9.
45. Moore AR, Willoughby DA. Hyaluronan as a drug delivery system for diclofenacs hypothesis for mode of action. Int J Tissue React 1995;17:153-6. (Pubitemid 26051692)
46. Pozo MA, Balazs EA, Belmonte C. Reduction of sensory responses to passive movements of inflamed knee joints by hylan, a hyaluronan derivative. Exp Brain Res 1997;116:3-9. (Pubitemid 27359190)
47. Gomis A, Miralles A, Schmidt RF, Belmonte C. Intra-articular injections of hyaluronan solutions of different elastoviscosity reduce nociceptive nerve activity in a model of osteoarthritic knee joint of the guinea pig. Osteoarthritis Cartilage 2009;17:798-804.
48. Glasziou P, Vandenbrocke JP, Chalmers I. Assessing the quality of research. BMJ 2004;328:39-41. (Pubitemid 38067746)
49. Black N. Why we need observational studies to evaluate the effectiveness of health care. BMJ 1996;312:1215-8. (Pubitemid 26136714)
50. von Elm E, Altmann DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Arch Dermatol 2007;4:e296 1623-7.
51. Bellamy N, Campbell J, Robinson V, Gee T, Bourne R, Wells G. Viscosupplementation for the treatment of osteoarthritis of the knee (Cochrane Review). The Cochrane Database Syst Rev 2006;2: CD005321. DOI:10.1002/14651858. CD005321.pub2.
52. Recommendations for the medical management of osteoarthritis of the hip and knee:2000 update. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Arthritis Rheum 2000;43:1905-15.
53. Zhang W, Moskowtiz RW, Nuki G, Abramson S, Altman RD, Arden N et al. OARSI recommendations for the management of hip and knee arthritis, part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage 2008;16:137-62. (Pubitemid 351222155)
54. EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: report of a task force of the Standing Committee for International Studies Including Therapeutic trials (ESCISIT). Ann Rheum Dis 2003;62:1145-55.